NHP · National Healthcare Properties, Inc.
Price & Indicators
The closing range uses available history since Apr 22, 2026; less than a full year is stored.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| OMF Same Store Cash NOI growth non-GAAP | -0.4% | Q2 2026 | — |
| OMF Same Store ending occupancy | 94.3% | Q2 2026 | — |
| SHOP Same Store average occupancy | 84.1% | Q2 2026 | — |
| SHOP Same Store Cash NOI growth non-GAAP | 20.1% | Q2 2026 | — |
| SHOP Same Store Cash NOI Margin non-GAAP | 22.4% | Q2 2026 | — |
| SHOP Same Store RevPOR | 5.9% | Q2 2026 | — |
| Adjusted EBITDA non-GAAP | $28.68M | Q1 2026 | — |
| FFO attributable to common stockholders non-GAAP | $8.73M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss attributable to common stockholders -7.6M
+16.41M Depreciation and amortization on real estate assets
+0K Impairment charges
+2K Loss (gain) on sale of real estate
-72K Depreciation on real estate assets related to non-controlling interests
= FFO attributable to common stockholders 8.73M
|
|||
| FFO per common share — Diluted non-GAAP | $0.31 | Q1 2026 | — |
| First quarter portfolio Same Store Cash Net Operating Income ("NOI") growth non-GAAP | 12% | Q1 2026 | — |
| Further Adjusted EBITDA non-GAAP | $28.69M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP Adjusted EBITDA 28.68M
+13K Adjustment for current period activity
= Further Adjusted EBITDA 28.69M
|
|||
| NOI non-GAAP | $33.37M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss attributable to common stockholders -7.6M
+0K Impairment charges
+53K Acquisition and transaction related
+5.47M General and administrative
+17.74M Depreciation and amortization
+2K Loss (gain) on sale of real estate investments
+14.67M Interest expense
-171K Interest and other (income) expense, net
-189K (Gain) loss on non-designated derivatives
+77K Income tax expense (benefit)
+28K Net (income) loss attributable to non-controlling interests
+3.29M Allocation for preferred stock
= NOI 33.37M
|
|||
| Normalized FFO attributable to common stockholders non-GAAP | $7.54M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP FFO attributable to common stockholders 8.73M
+53K Acquisition and transaction related
-1.39M Derivatives mark-to-market and terminations
+142K Casualty-related charges, net
-4K Normalizing items related to non-controlling interests
= Normalized FFO attributable to common stockholders 7.54M
|
|||
| Normalized FFO per common share — Diluted non-GAAP | $0.26 | Q1 2026 | — |
| OMF segment Cash NOI non-GAAP | $20.2M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP OMF segment NOI 20.6M
-268K Straight line rent adjustments
-141K (Accretion) amortization of market lease and other intangibles, net
= OMF segment Cash NOI 20.2M
|
|||
| OMF segment NOI non-GAAP | $20.6M | Q1 2026 | — |
| OMF segment Same Store Cash NOI non-GAAP | $20.31M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP OMF segment Cash NOI 20.2M
+18K Dispositions
+92K Redevelopment
= OMF segment Same Store Cash NOI 20.31M
|
|||
| OMF segment Same Store Cash NOI growth non-GAAP | 5.5% | Q1 2026 | — |
| Recurring Capital Expenditures non-GAAP | -$2.92M | Q1 2026 | — |
| Same Store average occupancy | 83.8% | Q1 2026 | — |
| Same Store Cash NOI Margin non-GAAP | 22.1% | Q1 2026 | — |
| Same Store ending occupancy | 94% | Q1 2026 | — |
| Same Store properties as of March 31, 2026 | 167 | Q1 2026 | — |
| SHOP segment Cash NOI non-GAAP | $12.76M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP SHOP segment NOI 12.76M
-6K Non-cash adjustments
= SHOP segment Cash NOI 12.76M
|
|||
| SHOP segment NOI non-GAAP | $12.76M | Q1 2026 | — |
| SHOP segment Same Store Cash NOI non-GAAP | $12.75M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP SHOP segment Cash NOI 12.76M
-4K Dispositions
= SHOP segment Same Store Cash NOI 12.75M
|
|||
| SHOP segment Same Store Cash NOI growth non-GAAP | 24% | Q1 2026 | — |
| Total properties as of March 31, 2026 | 168 | Q1 2026 | — |
| Average occupancy | 83.8% | the quarter ended March 31, 2026 | — |
| Full year 2025 dispositions | $202.5M | Year Ended December 31, 2025 | — |
| Net Leverage (Net Debt to Annualized Adjusted EBITDA) non-GAAP | 9.2 | As of December 31, 2025 | — |
| Same Store Cash NOI growth non-GAAP | 9.8% | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NHP
this stock
National Healthcare Properties, Inc.
|
$1.24B | — | -3.3% | — | 3.6% |
|
WELL
Welltower Inc.
|
$168.87B | +28.9% | +35.6% | 119.0 | 2.5% |
|
VTR
Ventas, Inc.
|
$47.73B | +20.3% | +18.5% | 172.3 | 4.6% |
|
DOC
Healthpeak Properties, Inc.
|
$14.76B | +33.1% | +4.5% | 61.1 | 3.5% |
|
OHI
Omega Healthcare Investors Inc
|
$14.12B | +5.1% | +13.2% | 16.6 | 4.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NHP | +3.5% | +6.0% | — | +10.9% | — |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +4.9% | +2.4% | — | +8.4% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.